Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News NY Valves 2024

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Michael O'Riordan

June 11, 2024

News Conference News STS 2024

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

Yael L. Maxwell

February 09, 2024

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

News Features

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Michael O'Riordan

January 06, 2023

News Conference News TVT 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Michael O'Riordan

June 10, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Daily News

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

Michael O'Riordan

September 28, 2020

News Daily News

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

Yael L. Maxwell

June 10, 2020

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Presentation TCT 2013

New (Open) Surgical Approaches to Aortic Valve Disease

Presenter: Michael Reardon

October 27, 2013

Advertisement

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Isolated vs Concomitant SAVR Offer Similar 5-Year Outcomes: PARTNER 3

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions

SAVR After Failed TAVR: Rare and Risky, Registry Study Finds

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

New (Open) Surgical Approaches to Aortic Valve Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content